Osanni Bio
Summary active Updated Jun 29, 2026This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.
Founders
About
Osanni Bio is a San Francisco-based therapeutics hub-and-spoke company founded by serial biotech entrepreneur Michael Ackermann, Ph.D. — whose prior companies include Tarsus Pharmaceuticals, Oyster Point Pharma (acquired by Viatris), Oculeve (acquired by Allergan) and Presidio Medical 123. Osanni operates a discovery engine that designs novel drug concepts, advances them to a meaningful proof-of-concept, and then graduates de-risked programs into an ecosystem of affiliate companies; its current pipeline spans ophthalmology, cardiology and oncology, with a dry AMD candidate among its programs 1234. The company was founded roughly three years ago with a $27 million Series A, and the June 2026 Series B was raised to scale the discovery platform and advance multiple programs 134.
Disclaimer: This is a lean profile built from initial round coverage and may be expanded as more information becomes available.
Funding History
| Date | Round | Amount | Lead | Co-investors |
|---|---|---|---|---|
| 2026-06-23 | Series B | $190M | Patient Square Capital | Horowitz Group, Invus Opportunities, Retinal Degeneration Fund 123 |
| ~2023 | Series A | $27M | — | — 13 |
What Investors Say
No independently sourced investor quotes found at the time of this round announcement.
What Founders Say
No independently sourced founder quotes found at the time of this round announcement.
Sources
-
BusinessWire (Osanni Bio press release), “Osanni Bio Closes $190 Million Series B Financing Led by Patient Square Capital,” June 23, 2026. Accessed June 2026. https://www.businesswire.com/news/home/20260623418949/en/Osanni-Bio-Closes-%24190-Million-Series-B-Financing-Led-by-Patient-Square-Capital↩↩↩↩↩
-
BioSpace, “Osanni Bio Closes $190 Million Series B Financing Led by Patient Square Capital,” June 23, 2026. Accessed June 2026. https://www.biospace.com/press-releases/osanni-bio-closes-190-million-series-b-financing-led-by-patient-square-capital↩↩↩
-
Fierce Biotech, “Discreet biotech Osanni Bio starts making noise with $190M series B for clinical push,” June 2026. Accessed June 2026. https://www.fiercebiotech.com/biotech/discreet-biotech-osanni-bio-starts-making-noise-190m-series-b-clinical-push↩↩↩↩↩
-
Talk Bio, “Osanni Bio raises $190M to advance ophthalmology and cardiology pipeline, including dry AMD candidate,” June 2026. Accessed June 2026. https://www.talk.bio/2026/06/osanni-bio-raises-190m-to-advance.html↩↩